NCT06681922View on ClinicalTrials.gov

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Graft Vs Host Disease
Interventions
DRUG

Cyclophosphamide, Bortezomib, Abatacept

Drug given for prevention of Graft-versus-Host Disease (GvHD) following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Trial Locations (1)

11042

RECRUITING

Zuckerberg Cancer Center, Lake Success

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER